1. Home
  2. MIRM vs SNX Comparison

MIRM vs SNX Comparison

Compare MIRM & SNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$67.51

Market Cap

3.4B

Sector

Health Care

ML Signal

HOLD

Logo TD SYNNEX Corporation

SNX

TD SYNNEX Corporation

HOLD

Current Price

$150.74

Market Cap

12.8B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
MIRM
SNX
Founded
2018
1980
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Retail: Computer Software & Peripheral Equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
12.8B
IPO Year
2019
2003

Fundamental Metrics

Financial Performance
Metric
MIRM
SNX
Price
$67.51
$150.74
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
10
Target Price
$87.55
$169.00
AVG Volume (30 Days)
560.0K
604.7K
Earning Date
11-04-2025
01-08-2026
Dividend Yield
N/A
1.13%
EPS Growth
N/A
18.98
EPS
N/A
9.21
Revenue
$471,794,000.00
$60,973,509,000.00
Revenue This Year
$53.78
$7.25
Revenue Next Year
$19.91
$4.50
P/E Ratio
N/A
$16.91
Revenue Growth
53.66
6.94
52 Week Low
$36.88
$92.23
52 Week High
$78.55
$167.76

Technical Indicators

Market Signals
Indicator
MIRM
SNX
Relative Strength Index (RSI) 46.96 45.42
Support Level $63.23 $148.97
Resistance Level $66.77 $158.68
Average True Range (ATR) 3.03 3.07
MACD -0.41 -0.04
Stochastic Oscillator 38.69 18.02

Price Performance

Historical Comparison
MIRM
SNX

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About SNX TD SYNNEX Corporation

TD Synnex Corp is a distributor and solutions aggregator for the IT ecosystem. The company aggregates and distributes IT hardware, software, and systems including personal computing devices and peripherals, mobile phones and accessories, printers, server and data center infrastructure, hybrid cloud, security, networking, communications and storage solutions, and system components. Its geographical segments include the Americas, Europe, and APJ.

Share on Social Networks: